tag:blogger.com,1999:blog-8550428.post110996843370980302..comments2024-03-28T13:38:36.788-04:00Comments on Pharma Marketing Blog: "Ethnic Drugs" and "Genetic Marketing"Vladhttp://www.blogger.com/profile/04114063498108633047noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-8550428.post-50936717451994838212007-01-21T20:56:00.000-05:002007-01-21T20:56:00.000-05:00I/d love to see the DTC for International Asian ma...I/d love to see the DTC for International Asian markets and compare to US-based Asian marketsAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-8550428.post-1115229687155957712005-05-04T14:01:00.000-04:002005-05-04T14:01:00.000-04:00The following is another example of ethnicity and ...The following is another example of ethnicity and drugs. It is interesting to note that it encompasses the idea of "Evidence-based Marketing" I espoused in another post (see <A HREF="http://pharmamkting.blogspot.com/2005/04/evidence-based-marketing.html" REL="nofollow">Evidence-based Marketing</A>).<BR/><BR/>Cancer Drug Helps Asians Even as It Fails In Other Groups<BR/><BR/>THE WALL STREET JOURNAL<BR/>May 4, 2005<BR/><BR/>When a large clinical trial showed lung-cancer drug Iressa was largely ineffective at prolonging patients' lives, it looked like the end of the line for one of AstraZeneca PLC's most promising drugs. The U.S. Food and Drug Administration started and continues to review whether to pull the drug from the market.<BR/><BR/>But a curious quirk in how the medicine works now offers some hope.<BR/><BR/>Iressa has proved effective at treating lung cancer in Asian patients, even as it has flopped in treating Caucasians, blacks and just about everybody else. Asians respond well to the therapy because they are more likely to have a certain genetic mutation in their cancer cells that Iressa is good at targeting, scientists believe. As a result, AstraZeneca, which initially planned on big sales of Iressa in the U.S., is now adjusting its marketing plan to focus on Japan, China and other Asian markets.PharmaGuyhttps://www.blogger.com/profile/10211557578124130640noreply@blogger.comtag:blogger.com,1999:blog-8550428.post-1111516210657616222005-03-22T13:30:00.000-05:002005-03-22T13:30:00.000-05:00Dear Sir, I enjoyed this article very much ! I'm w...Dear Sir, I enjoyed this article very much ! I'm working in the area of human genetics and brain development and have been following the development of the "personalized medicine era" from the sidelines with the hope that genetics might become a more utilized tool for the treatment of neuropsychiatric disorders. Has anyone looked in a formal way at how marketing strategies would adapt from the 'one size fits all' to the 'genotype-specific' therapy ? Would the dna banking and/or direct to consumer strategies come into play ? I'd like to contribute my expertise in human genetics to the analysis of these questions if there is an interest. Regards, John Fossella PhD, Weill Medical College Cornell University (jaf2014@med.cornell.edu)Anonymousnoreply@blogger.com